Drug Trial Radar · NCT02045901
A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Last checked: Nov 19, 2026Latest source record: Nov 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
131
Actual
Start
Feb 2014
Primary completion
Mar 31, 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- Duchesnay Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Premier Research
- First posted
- Jan 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 12 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the efficacy of Diclegis for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Diclegis in pregnant adolescents aged 12 to 17 years with placebo by assessing differences in the severity and occurrence of maternal adverse events (AEs).
Conditions
- Morning Sickness
Interventions
DiclegisDrug
On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Placebo (Sugar Pill)Drug
On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nausea and Vomiting of Pregnancy Severity from Baseline to Day 15Time frame: Day 1-Day 15
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Watching Over Mothers and Babies
Tucson, Arizona
Clinica Del Socorro Medical Group, Inc.
Los Angeles, California
Futura Research
Norwalk, California
Medical Professional CR Center
Miami, Florida
Empire Clinical Research, LLC
Miami Lakes, Florida
Western Michigan University Homer Stryker M.D. School of Medicine
Kalamazoo, Michigan
Jersey Shore University Medical Center
Neptune City, New Jersey
Complete Healthcare for Women
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.